A cell transmembrane peptide chimeric M(27–39)-HTPP targeted therapy for hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a prevalent malignant tumor, with a growing incidence and death rate worldwide. The aims and challenges of treating HCC include targeting the tumor, entering the tumor tissue, inhibiting the spread and growth of tumor cells. M27-39 is a small peptide isolated from the antimicrobial peptide Musca domestica cecropin (MDC), whereas HTPP is a liver-targeting, cell-penetrating peptide obtained from the circumsporozoite protein (CSP) of Plasmodium parasites. In this study, M27-39 was modified by HTPP to form M(27–39)-HTPP, which targeted tumor penetration to treat HCC. Here, we revealed that M(27–39)-HTPP had a good ability to target and penetrate the tumor, effectively limit the proliferation, migration, and invasion, and induce the apoptosis in HCC. Notably, M(27–39)-HTPP demonstrated good biosecurity when administered at therapeutic doses. Accordingly, M(27–39)-HTPP could be used as a new, safe, and efficient therapeutic peptide for HCC.